TabMenu

Poverty and InequalitySexual and Reproductive HealthFamily, Maternal & Child HealthMethodology

Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation

TitleEtiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation
Publication TypeJournal Article
Year of Publication2018
AuthorsAbubakar, M, Chang-Claude, J, Ali, HR, Chatterjee, N, Coulson, P, Daley, F, Blows, F, Benitez, J, Milne, RL, Brenner, H, Stegmaier, C, Mannermaa, A, Rudolph, A, Sinn, P, Couch, FJ, Devilee, P, Tollenaar, R, Seynaeve, C, Figueroa, J, Lissowska, J, Hewitt, S, Hooning, MJ, Hollestelle, A, Foekens, R, Koppert, LB, Investigators, K, Bolla, MK, Wang, Q, Jones, ME, Schoemaker, MJ, Keeman, R, Easton, DF, Swerdlow, AJ, Sherman, ME, Schmidt, MK, Pharoah, PD, Garcia-Closas, M
JournalInt J Cancer
Volume143
Pagination746-757
Date PublishedAug 15
ISBN Number0020-7136
Accession Number29492969
Keywordsbreast cancer, Epidemiology, grade, hormone therapy, Ki67, nulliparity, Obesity, proliferation
Abstract

Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case-case and case-control comparisons for risk factors in relation to levels of grade and quartiles (Q1-Q4) of KI67 were estimated using polytomous logistic regression models. Case-case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1 = 1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1 = 1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1 = 0.27 (0.16, 0.44)] tumors. In case-control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women >/=50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors.

PMCID

PMC6041155